<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Top 10 Questions: HUB Organoid Technology and Models

Dr Rajendra Kumari answers key questions around HUB Organoid Technology and tumor organoid modelsDr Rajendra Kumari answers the key questions around HUB Organoid technology and tumor organoid models from our recent webinar on 3D in vitro drug discovery.

HUB Organoid Models and Development

Why do Tumor Organoids Develop from Adult Stem Cells?

Stem cells are under-differentiated cells with self-renewing capacity and the potential to regenerate various tissues and organs. HUB methods use stem cell niche factors to stimulate these stem cells to proliferate and differentiate, so you don’t get an enrichment for stem cells as the differentiated cells continue to grow.

Can Models also be Established for Mimicking Cancer Stem Cells?

3D spheroids are typically used for cancer stem cell enrichment, rather than organoids, as the cells are able to differentiate.

Could You Discuss the Important Differences between Patient-Derived Spheroids and Patient-Derived Organoids?

Spheroids are cell clusters or aggregates of single cell populations or a mixture of different cells, typically immortalized cell lines, primary cells, or fragments of human tissue. This is different to organoids which are developed from stems cells and have multiple cell lineages developed as a result of self-organization. Organoids also have a 3D shape and structure resembling the microanatomy of the tissue from which they originate.

Spheroids can mimic different proliferative and quiescent phenotypes as well as drug penetrance and resistance and hypoxia, but cannot be maintained in long term culture and undergo senescence. In contrast, organoids have the ability to be maintained in long term culture. We've covered this is more detail in a previous blog post.

Have You Also Established 3D Models Mimicking Normal Tissue to Study Drug Side Effects?

We do have ‘normal’ organoids from HUB, which are currently being expanded. HUB organoids are being used by others for toxicity testing whereas we are focusing on preclinical oncology.

Are Normal Organoids Matched to Tumor Organoids?

Yes, matched pairs have been generated by HUB using normal tissue adjacent to tumors.

You Have Solid Tumor Derived Organoids Available, but not Organoids from Leukemia or Lymphoma. Can You Explain Why?

Currently the HUB method for culturing organoids is only valid for epithelial origin cells and therefore we don’t have organoids for lymphoma or leukemia. We can use lymphoma PDX ex vivo for 3D cultures.

HUB Organoid Model Technical Questions

How do you Passage HUB Organoid Cultures?

We are trained by HUB and they advise on the best approach for passaging. We cannot explicitly share this information, but there are many published methods and online information available.

Are the Organoids Single Cell Detached and then Seeded For Drug Screening?

These are plated as organoids.

Do you Change Media Every Day during Drug Screens, to Replace Growth Factors?

No, the organoids are plated at a density so not to deplete the available nutrients in culture - they are incubated in the assay for 5 days.

Have you tested PDO-Like 3D Cell Cultures in a "Prematuration" Phase, e.g. Prior to the Multi-Week Expansion Step?

We work to build a master cell bank first and this varies in terms of passage for each model. This is then characterized once we know the growth of an organoid can be achieved and has been SNP verified. From this a working cell bank is developed and again SNP verified so we don’t test in any early stages.

Contact us with any further questions on our organoid platform and models.


Related Posts